Project Grant R15AG103945
- The National Institute on Aging, part of the National Institutes of Health, awarded $1,250,191 to the University of North Carolina at Chapel Hill on February 15, 2026, under the Aging Research program (CFDA 93.866) to develop an integrated artificial intelligence and experimental workflow for accelerating discovery of small-molecule modulators that influence Alzheimer's disease through microglial phagocytosis regulation. The funded work combines AI-driven computational methods with...
- The National Institute on Aging awarded the University of California, Berkeley $549,260 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop advanced large language model-based AI tools that enhance precision in predicting Alzheimer's disease pathology and cognitive outcomes. The research addresses critical gaps in precision medicine for Alzheimer's disease, particularly the need to capture patient heterogeneity, accurately identify treatment candidates for...
- The National Institute on Aging, under the Department of Health and Human Services, awarded Duke University $627,830 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop a portable diagnostic system for Alzheimer's disease detection using circulating microRNA biomarkers. Duke's project, titled ADMIRE (Alzheimer's Detection via miRNA Evaluation), integrates two technologies: an amplification-free microRNA biosensing modality called the Inverse Molecular Sentinel and a...
- The National Institute on Aging awarded the University of Washington $1,212,446 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal analysis of multi-omics biomarkers and their association with cognitive decline and dementia. The recipient will leverage serial multi-omics data with deep phenotyping to map mechanisms of cognitive decline and dementia and nominate druggable targets. The work uses two discovery and replication cohorts: the Cardiovascular...
- The National Institute on Aging awarded Wake Forest University Health Sciences $633,510 on September 1, 2026, under the Aging Research program (CFDA 93.866) to examine the impact of home-based medical care and telemedicine use on dementia care outcomes among Medicare enrollees with Alzheimer's disease and related dementias. The project will study home-based medical care delivery—house calls by physicians and advanced care providers—and telemedicine use among persons living with Alzheimer's...
- The National Institute on Aging awarded the University of Washington $575,342 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop statistical and artificial intelligence tools that elucidate cognitive resilience in Alzheimer's disease by linking region-resolved neuropathology with cell-type programs, particularly microglia function. The project integrates quantitative digital neuropathology with single-cell and spatial molecular profiles to build methods that estimate...
- The National Institute on Aging awarded Duke University $1.597 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to support research on epitranscriptomic regulation of microglia in Alzheimer's disease. The research investigates how m6a methylation of adenosine residues in messenger RNA regulates microglial cell function and transitions between resting and activated states during Alzheimer's disease pathogenesis, with the goal of identifying novel...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded Emory University $643,613 on April 1, 2026, under the Aging Research program (CFDA 93.866) to discover glycosylation-based disease processes and identify glyco-biomarkers and targets for improving Alzheimer's disease diagnosis, prognosis, and intervention. The recipient will perform innovative research using an integrated platform of intact glycopeptide-based quantitative glycoproteomics and systems biology to elucidate brain glycoproteome alterations in...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
The National Institute on Aging awarded $526,607 to Wake Forest University on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop computational imaging frameworks that integrate neuroimaging with multi-omics data to identify Alzheimer's disease subtypes and model neurodegenerative progression with calibrated uncertainty. The project, titled "Neuroimaging Multi-Omics Fingerprints for Subtyping and Uncertainty-Aware Prediction of Alzheimer's Disease," will construct knowledge-guided graphs to characterize multimodal imaging-omics interactions and identify interpretable AD subtypes, and design uncertainty-aware deep learning models to forecast neurodegenerative and cognitive trajectories. The work uses ANMERGE data for model development and discovery, with generalizability evaluation on complementary datasets (AMP-AD and ADNI). The award funds research performed in Winston-Salem, North Carolina, with a period of performance extending through August 31, 2029. Successful completion will yield novel deep learning algorithms that unify multi-omics and neuroimaging data to reveal interpretable subtypes and generate uncertainty-aware disease predictions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $526.6k | 8/13/26 |